In EGFR‐mutant NSCLC, oncogenic signalling by constitutive active EGFR is mediated via the RAS/RAF/MEK/ERK (MAPK) and/or PI3K/AKT signalling pathways. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.